LSL Web-Exclusive Content

  1. How Biotechs Can Manage Risk and Efficiency in a Changing Healthcare Landscape

    When preparing for product commercialization, biotechs need to assess internal capacity and capabilities with the following goals in mind:

  2. New Regulations And Safety Complicate Drug Labeling

    Multinational pharmaceutical companies have for decades manufactured drugs for global distribution. Nevertheless, the task of labeling is becoming increasingly difficult and time-consuming. 

  3. Succeeding In The Latin American Medtech Market: Three Tips, Five Trends

    Latin America is developing into a sizable, predictable part of the global medical device market, allowing foreign manufacturers to have sustainable commercial operations.

  4. Can Real-World Evidence Improve Market Access For Biosimilars In The U.S.?

    A look at the role real-world evidence (RWE) can play in increasing the uptake of biosimilars in the U.S. market and some of the challenges in leveraging the potential of RWE.

  5. Despite Theranos, Real, Capital-Efficient Innovation Exists For Blood Tests

    While the Theranos scandal was a disappointment, recent studies in liquid biopsies demonstrate that real, capital-efficient innovation is alive and well.

  6. Email: Friend Or Foe Of Effective Communication In Clinical Trials?

    There are some easy ways to improve communication on your clinical trial. But before we get into that, let’s consider how poor communication can derail your clinical trial.

  7. The State Of Pharma Litigation After The Supreme Court’s TC Heartland Case

    A look at ANDA litigations and the necessity of understanding where the “act of infringement” has occurred to determine if venue is proper in pharmaceutical litigation.

  8. How Will The Federal Right To Try Law Impact Drug Development?

    The passing of the Right to Try Act came after years of debate among politicians, the pharmaceutical industry, and other stakeholders about the potential legal, ethical, regulatory, and business impacts of RTT. That debate is unlikely to end any time soon.

  9. Pharma’s Battle To Stamp Out Transparency Laws

    States are moving to control rising drug prices, and pharma is fighting back.

  10. 5 Keys To Unlock The Full Potential Of Big Data In The Life Sciences

    The convergence of data and technologies provides an opportunity for companies to make a step change in innovation and performance. Those that successfully apply the strategies to all parts of the business will thrive in an increasingly complex sector.